Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics making strides in medical cannabis research

Zelda continues to ramp up its clinical trial activities in Chile.
Zelda Therapeutics making strides in medical cannabis research
Chile provides support for medical cannabis research

Zelda Therapeutics Ltd (ASX:ZLD) is making significant progress with its medical cannabis research program in Chile.

The company has already established a focus on autism, eczema and insomnia.

Zelda has now engaged the services of an experienced team of clinicians and scientists to help manage its clinical trials.

Harry Karelis, executive chairman, commented:

"We welcome Dr Kuester, Dr Sasso and Ms Vergara to our research team and are delighted to have such a high calibre local team coordinating our activities in Chile.

"Zelda is steadily progressing towards commencement of its clinical trial program in Chile and I look forward to providing shareholders positive updates in due course."

Why Chile

Zelda has strategically focused on conducting its research activities in Chile due to the efficiency of its legal and regulatory framework, cost effectiveness and its market access into the large South American pharmaceutical market.

The Chilean government granted permission for the first cannabis crop to be planted for medicinal purposes in 2015, and has subsequently allowed the sale of medicinal cannabis in pharmacies.

This has given rise to researchers and organisations specialising in medicinal cannabis treatments.

Zelda has capitalised on this, forming strategic alliances with world-class researchers and physicians, and has access to valuable patient data which will assist in the development of robust clinical trials.

View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 19 2017
John Martin discussed regenerative medicine with investors.
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use